Supplementary Figure 5.

Rituximab treatment after re-implantation of a Mixed PDXs prevents lymphoma formation.

The gastric tumor from patient GTR0237 (upper panels) originated a Mixed Lymphoma in the first passage in mouse (P1, middle panels and enlargements). The mixed tumor was s.c transplanted in a second mouse (P2, lower panels and enlargements) treated with Rituximab i.p. 25 mg/kg 3 times/week for 1 week and once a week for the following 3 weeks (Ritux). As shown, Rituximab treatment allowed growth of a tumor with features of pure adenocarcinoma. H&E, pan-cytokeratin and CD20 staining confirmed the different histology of the P1 and P2 PDXs.